Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cytomx Thera (CTMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 450,659
  • Shares Outstanding, K 45,111
  • Annual Sales, $ 59,500 K
  • Annual Income, $ -84,600 K
  • 60-Month Beta 0.68
  • Price/Sales 7.67
  • Price/Cash Flow N/A
  • Price/Book 3.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.53
  • Number of Estimates 7
  • High Estimate -0.46
  • Low Estimate -0.59
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -32.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.73 +2.67%
on 04/18/19
11.69 -14.54%
on 04/08/19
-0.76 (-7.07%)
since 03/18/19
3-Month
9.38 +6.50%
on 03/11/19
19.75 -49.42%
on 02/05/19
-6.77 (-40.39%)
since 01/18/19
52-Week
9.38 +6.50%
on 03/11/19
27.34 -63.46%
on 04/23/18
-17.69 (-63.91%)
since 04/18/18

Most Recent Stories

More News
Market Trends Toward New Normal in CNH Industrial N.V, Valero Energy, Paychex, TriMas, Euronet Worldwide, and CytomX Therapeutics -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CNH Industrial N.V. (NYSE:CNHI),...

CNHI : 11.23 (-0.53%)
CTMX : 9.99 (-1.28%)
TRS : 32.41 (+0.28%)
PAYX : 81.59 (+0.04%)
VLO : 88.04 (-1.54%)
EEFT : 147.42 (-1.03%)
AACR 2019 Presentations Highlight CX-2009, a First-In-Class Probody Drug Conjugate Targeting Novel Tumor Antigen, CD166

- PROCLAIM-CX-2009 Dose Escalation Study Demonstrates Anti-Tumor Activity in Multiple Tumor Types -

CTMX : 9.99 (-1.28%)
CytomX Therapeutics Announces Transition of Chief Financial Officer

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 9.99 (-1.28%)
19.4% Return Seen to Date on SmarTrend Cytomx Therapeut Call (CTMX)

SmarTrend identified a Downtrend for Cytomx Therapeut (NASDAQ:CTMX) on February 27th, 2019 at $12.97. In approximately 4 weeks, Cytomx Therapeut has returned 19.40% as of today's recent price of $10.45....

CTMX : 9.99 (-1.28%)
Cytomx Therapeut Has Returned 19.8% Since SmarTrend Recommendation (CTMX)

SmarTrend identified a Downtrend for Cytomx Therapeut (NASDAQ:CTMX) on February 27th, 2019 at $12.97. In approximately 2 weeks, Cytomx Therapeut has returned 19.78% as of today's recent price of $10.40....

CTMX : 9.99 (-1.28%)
CytomX to Present at Upcoming Healthcare Conferences

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody(TM) therapeutic...

CTMX : 9.99 (-1.28%)
CytomX Therapeutics Announces Full-Year 2018 Financial Results

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 9.99 (-1.28%)
Shares of CTMX Up -13.3% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Cytomx Therapeut (NASDAQ:CTMX) on January 4th, 2019 at $15.32. In approximately 2 months, Cytomx Therapeut has returned 13.25% as of today's recent price of $13.29....

CTMX : 9.99 (-1.28%)
CytomX Therapeutics 2019 Research and Development Day Highlights Clinical Data from Lead Programs and the Broad Potential of Probody(TM) Therapeutic Platform

- CX-2009, a First-in-Class Probody Drug Conjugate Targeting CD166, Demonstrates Encouraging Anti-Cancer Activity in Multiple Tumor Types and Safety in Phase 1 Dose Escalation -

CTMX : 9.99 (-1.28%)
Analysis: Positioning to Benefit within Jacobs Engineering Group, Ares Capital, CytomX Therapeutics, FuelCell Energy, Timken, and Farmland Partners -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Jacobs Engineering Group Inc....

CTMX : 9.99 (-1.28%)
FCEL : 0.22 (unch)
JEC : 76.93 (+0.21%)
TKR : 47.93 (+0.21%)
FPI : 6.58 (+0.61%)
ARCC : 17.35 (+0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CTMX with:

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 10.51
1st Resistance Point 10.25
Last Price 9.99
1st Support Level 9.73
2nd Support Level 9.47

See More

52-Week High 27.34
Fibonacci 61.8% 20.48
Fibonacci 50% 18.36
Fibonacci 38.2% 16.24
Last Price 9.99
52-Week Low 9.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar